Alvotech Cash Flow Conversion Efficiency
Alvotech cash flow conversion efficiency. Based on the latest financial reports, Alvotech (ALVO) has a cash flow conversion efficiency ratio of 0.314x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Ikr-55.58 Million ≈ $-453.08K USD) by net assets (Ikr-176.76 Million ≈ $-1.44 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Alvotech (2020–2024)
Cash flow conversion efficiency of Alvotech from 2020 to 2024. This chart illustrates how Alvotech's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Alvotech (ALVO) share price today for real-time trading data and today's change.
Alvotech Cash Flow Conversion Ratio Explained
Alvotech cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Alvotech Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alvotech ranked by their cash flow conversion efficiency. Also see ALVO market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sitronix Technology Corp
TW:8016
|
0.064x |
|
Chang Wah Electromaterials Inc
TW:8070
|
0.037x |
|
Arendals Fossekompani ASA
OL:AFK
|
0.013x |
|
Blue Dart Express Limited
NSE:BLUEDART
|
0.152x |
|
Hartalega Holdings Bhd
KLSE:5168
|
0.013x |
|
Beijing Winsunny Pharmaceutical CO.LTD
SHG:601089
|
N/A |
|
Beijing Strong Biotechnologies Inc
SHE:300406
|
0.046x |
|
Tompkins Financial Corporation
NYSE MKT:TMP
|
0.044x |
Annual Cash Flow Conversion Efficiency for Alvotech (2020–2024)
The table below shows the annual cash flow conversion efficiency of Alvotech from 2020 to 2024. Review Alvotech (ALVO) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Ikr-412.77 Million ≈ $-3.37 Million |
Ikr-236.84 Million ≈ $-1.93 Million |
0.574x | +71.39% |
| 2023-12-31 | Ikr-932.49 Million ≈ $-7.60 Million |
Ikr-312.19 Million ≈ $-2.55 Million |
0.335x | -39.51% |
| 2022-12-31 | Ikr-564.42 Million ≈ $-4.60 Million |
Ikr-312.39 Million ≈ $-2.55 Million |
0.553x | -67.10% |
| 2021-12-31 | Ikr-135.61 Million ≈ $-1.11 Million |
Ikr-228.17 Million ≈ $-1.86 Million |
1.683x | +1864.00% |
| 2020-12-31 | Ikr-867.24 Million ≈ $-7.07 Million |
Ikr-74.30 Million ≈ $-605.70K |
0.086x | -- |
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic art… Read more